The Worldwide Growth Stimulator Industry is Expected to Reach $1.8 Billion by 2027 – ResearchAndMarkets.com

The Worldwide Growth Stimulator Industry is Expected to Reach $1.8 Billion by 2027 - ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Bone Growth Stimulator Market by Product (Device (External Bone Growth Stimulators), Platelet-Rich Plasma), Application (Spinal Fusion Surgeries, Oral & Maxillofacial Surgeries), End Users (Hospital, Ambulatory surgical centers) – Global Forecast to 2027” report has been added to ResearchAndMarkets.com’s offering.

The global bone growth stimulators market is valued at an estimated USD 1.8 billion by 2027 from an estimated USD 1.36 billion in 2022, at a CAGR of 5.9% from 2022 to 2027 during the forecast period.

The growing demand for bone growth stimulators in spinal fusion surgeries applications; the rising preference for non-surgical and non-invasive treatment.

The bone growth stimulator devices segment accounted for the highest growth rate in the bone growth stimulation devices market, by product, during the forecast period.

Based on product, the global bone growth stimulation devices market is segmented into External Bone Growth Stimulators, Ultrasonic Bone Growth Stimulators and Implanted Bone Growth Stimulators. In 2021, the external Bone Growth Stimulators segment accounted for the largest share of the global bone growth stimulators market.

This segment is also expected to grow at the highest rate during the forecast period. The largest share of this segment can be attributed to the advantages of external devices over internal/implanted devices, these are less expensive, noninvasive, and do not require surgeries for implantation and removal which will drive the market growth.

The spinal fusion surgeries segment accounted for the highest CAGR.

On the basis of application, the global bone growth stimulators market is segmented into – spinal fusion surgeries, delayed union and nonunion bone fractures, oral and maxillofacial surgeries, and other applications. In 2021, the spinal fusion surgeries segment accounted for the largest share of the bone growth stimulators market. Factors supporting the growth increasing the growing geriatric population and the rising number of spine procedures.

The Asia-Pacific market is expected to grow at the highest CAGR during the forecast period.

The bone growth stimulators market is segmented into – North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The bone growth stimulators market in several Asia-Pacific countries is expected to witness high growth during the forecast period owing to the ageing population, rapid economic growth in emerging APAC countries and rising volume of spine procedures.

Market Dynamics

Drivers

Growing Patient Preference for Noninvasive and Minimally Invasive Surgical Treatments

Increasing Target Patient Population

Rising Number of Sports and Accident-Related Orthopedic Injuries

Rising Geriatric Population

Restraints

Limited Medical Reimbursement for Bone Stimulation Products

High Treatment Costs Associated with Bmp and Prp Products

Limited Clinical Evidence to Support Therapeutic Efficacy of Bone Growth Stimulators

Opportunities

Emerging Markets

Increasing Use of Prp in Other Applications

Rising Number of Hospitals and Surgical Centers

Challenges

Lack of Access to Diagnostics

Side Effects Associated with Bmp-Based Orthopedic Treatment

Companies Mentioned

Altis Biologics (Pty) Ltd.

Arthrex, Inc.

Bioventus LLC

BTT Health GmbH

Depuy Synthes

Elizur Corporation

Ember Therapeutics, Inc.

Enovis Corporation (Formerly Colfax)

Isto Biologics

ITO Co., Ltd.

Kinex Medical Company, LLC

Medtronic plc

Orthofix Medical Inc.

Ossatec Benelux Ltd.

Regen Lab Sa

Stimulate Health

Stryker

Terumo Corporation

VQ Orthocare

Zimvie Inc. (Subsidiary of Zimmer Biomet)

For more information about this report visit https://www.researchandmarkets.com/r/wcmgiv

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Businesswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, businesswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Subscribe to receive exclusive content and notifications to your inbox

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.